PVG Escalates Proxy Fight With New Allegations Against Anavex CEO and Chairman
AVXL sits 19% above its 52-week low of $2.255.
Summary
PVG Asset Management issued a new press release adding specific allegations about the CEO's short tenure and the Chairman's SPAC track record, while highlighting minimal insider ownership and a $1.3 million proxy fight budget.
Key Events · Corporate Governance and Compliance · AVXL
-
New CEO Tenure Allegations
PVG claims the current CEO held five positions across four organizations in seven years, none longer than about 27 months, and that during her tenure as Aardvark's EVP of Regulatory Affairs, that company paused its Phase 3 HERO trial on February 27, 2026.
-
Chairman's SPAC Track Record Attacked
PVG alleges Chairman Jiong Ma was involved in Chavant Capital Acquisition Corp., a SPAC that merged with Mobix Labs, whose stock declined from about $100 to about $1.70 per share, a -98% decline.
-
Minimal Insider Ownership Highlighted
PVG states the four current Board nominees collectively own just 5,000 shares, with three of the four owning zero shares.
-
$1.3M Proxy Fight Budget Disclosed
PVG claims the Company has disclosed a budget of $1.3 million for the proxy contest to defend the incumbent board.
Analysis · AVXL · Life Sciences
PVG Asset Management's latest proxy solicitation adds several new, specific allegations against Anavex's leadership: the current CEO held five positions in seven years with none lasting longer than 27 months, and during her tenure at Aardvark that company paused its Phase 3 HERO trial. PVG also attacks Chairman Jiong Ma's track record, citing a SPAC merger that saw Mobix Labs stock fall from about $100 to $1.70. The filing claims the four current Board nominees collectively own just 5,000 shares, with three owning zero, and that the Company has budgeted $1.3 million for the proxy fight. These new details sharpen the activist's case ahead of the September 24, 2026 annual meeting, where PVG is seeking to replace the entire board with its six nominees.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVXL was trading at $2.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $254.9M. The 52-week trading range was $2.26 to $10.40. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.